Emerging advances in engineered macrophages for tumor immunotherapy

Area of Science:

• Immunology
• Oncology
• Biotechnology

Background:

• Macrophages are crucial antigen-presenting cells with potential in cancer therapy.
• The tumor microenvironment often suppresses anti-tumor immune responses.
• Engineered macrophages offer novel therapeutic strategies for solid tumors.

Purpose of the Study:

• To analyze the impact of chimeric antigen receptor (CAR) platforms on macrophage engineering.
• To review current engineering modifications of macrophages for cancer treatment.
• To highlight the status, challenges, and future directions of engineered macrophage therapy.

Main Methods:

• In vitro gene editing of macrophages.
• Development of cellular drug delivery systems using macrophages.
• Analysis of CAR platform efficacy in macrophage engineering.
• Review of non-genetic engineering tools targeting immunosuppressive pathways.

Main Results:

• Engineered macrophages, particularly with CARs, can overcome tumor-induced immunosuppression.
• In vitro gene-edited macrophages demonstrate potential for solid tumor therapy.
• Macrophages can be modified for targeted drug delivery and enhanced anti-tumor activity.

Conclusions:

• Engineered macrophages represent a promising therapeutic avenue for solid tumors.
• The CAR platform offers significant potential for enhancing macrophage-based cancer immunotherapy.
• Future research should focus on overcoming challenges and optimizing engineered macrophage strategies for clinical application.